30 Billion Yuan for China’s Obesity Drug Market After Lilly Pill Approval
Key Facts
China’s drug regulator approved Eli Lilly’s orforglipron weight-loss pill on November 12, 2026, the first Chinese approval of a GLP-1 pill for this purpose, Reuters reported. The move comes as annual sales of GLP-1 weight-management treatments in China could rise to 30 billion yuan in five to seven years, compared with a current estimate of between 3 and 4 billion yuan, according to JPMorgan’s head of China healthcare research. The decision gives Lilly an early regulatory advantage in the market for oral obesity treatments, but does not by itself determine when commercial sales will begin. The company said it was working to bring forward the commercial launch in China. Lilly did not comment on the price, Reuters reported.
The pill enters a market where approved GLP-1 drugs for weight management have been administered by injection, Reuters reported. Orforglipron will compete with Lilly’s weekly injection, as well as similar injections from Novo Nordisk, Pfizer and China’s Innovent. The shift of competition to pills adds an oral option to a category that has so far relied on injections in China. Chinese authorities accepted Novo Nordisk’s application in August 2026 to market the oral version of Wegovy, but Reuters did not report a timeline for the company’s approval. Lilly has therefore moved ahead of its Danish rival in securing Chinese approval for a GLP-1 weight-loss pill, while approval of Novo’s application remains unconfirmed in the available facts.
The market response came in U.S. premarket trading on the day the approval was announced, with Lilly shares up 1.2% and Novo Nordisk shares rising more than 2%, Reuters reported. Another report said Lilly shares rose 2.8% in premarket trading on Thursday, after China approved orforglipron. The two figures reflect moves reported by separate outlets during the announcement session and do not represent daily closes. EL7 data also showed Lilly shares closing at 1,427.28 on November 12, 2026. The move coincided with a regulatory decision that opens a large pharmaceutical market to Lilly, as an analyst expects sales of the category to multiply from current levels.
The market’s growth opportunity rests on a broad population that may need weight management. China’s National Health Commission said the share of adults who are overweight or obese could reach 65.3% by 2030, up from about 50% in 2020, according to a report published by China’s State Council; the projection was based on a commission report issued in 2020. In terms of ease of use, orforglipron can be taken without restrictions related to food or water, according to the Associated Press. The oral version of Wegovy, meanwhile, is taken in the morning on an empty stomach, with a 30-minute wait before eating or drinking. The difference in how the pills are taken places them in a competitive landscape shaped not only by efficacy but also by daily-use requirements.
Lilly’s quarterly results offered an indication of its products’ presence in the obesity-treatment market, though they are not a measure of orforglipron sales in China. The company’s global revenue was 24.4 billion dollars in the third quarter of 2026, up 39% from the same quarter in 2025, according to its financial results. Foundayo, one of the company’s oral weight-loss treatments, recorded revenue of 184 million dollars in the quarter. Lilly also said realized prices outside the United States fell mainly because Mounjaro was added to China’s national reimbursable drug list. This highlights one aspect of the pricing environment that new products are entering, alongside competition for patients and market share.
The next step is to turn regulatory approval into a commercial launch. Lilly said it was working to accelerate the rollout of orforglipron in China and would supply the drug to approved healthcare and pharmaceutical institutions, Reuters reported. The company did not announce a price for the drug in the agency’s report. Novo said in August that its application to market the oral version of Wegovy had been accepted, but Reuters did not specify when a decision would be issued. At the company level, Lilly raised its 2026 revenue guidance to a range of between 91 and 92 billion dollars, according to its third-quarter results statement. The 30 billion yuan estimate remains a forecast for total sales of the category across China in five to seven years, not an estimate of revenue for orforglipron or Lilly alone.